Loading...
Projects / Programmes
Preclinical development of a novel inhibitor of class A and class C beta-lactamases
Research activity
| Code | Science | Field | Subfield |
|---|---|---|---|
| 1.09.00 | Natural sciences and mathematics | Pharmacy |
| Code | Science | Field |
|---|---|---|
| B230 | Biomedical sciences | Microbiology, bacteriology, virology, mycology |
| B510 | Biomedical sciences | Infections |
| B740 | Biomedical sciences | Pharmacological sciences, pharmacognosy, pharmacy, toxicology |
Keywords
bacterial resistance, new chemical entities
Evaluation
(metodology)
Citations
Citations for bibliographic records in COBIB.SI that are linked to records in citation databases
Organisations (1) , Researchers (2)
0258 Lek Pharmaceutical Company d.d.
| no. | Code | Name and surname | Research area | Role | Period | No. of publicationsNo. of publications |
|---|---|---|---|---|---|---|
| 1. | 20246 | Biochemistry and molecular biology | Researcher | 2005 - 2007 | 38 | |
| 2. | 01661 | Chemistry | Head | 2005 - 2007 | 380 |
Abstract
Careful biological evaluation in vitro is key to understand the basis of the antibacterial activity, guiding chemical refinement and assisting subsequent stages providing preliminary indications and evaluations of therapeutic potential.Small-scale screening/initial evaluation of antibacterial potency will be performed (IC50s and Biacore-SPR ranking of all new chemical entities).Clinically relevant pathogens will be employed to establish the antibacterial activity of lead in combination with different (3-lactam antibiotics (In vitro MICs, susceptibility profile).Finally, the project will contribute a vast amount of knowledge to the antimicrobial field. New techniques introduced will represent a screening platform for in-house drug profiling.